Tags

Type your tag names separated by a space and hit enter

High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders.
J Clin Psychopharmacol. 2017 Apr; 37(2):231-238.JC

Abstract

BACKGROUND

Drug-related movement disorders (DRMDs) reduce quality of life and contribute to medication noncompliance of patients with psychotic disorders. Little is known about the epidemiology of DRMDs in relatively young patients a few years after onset of psychosis. This is an important period to study, as the impact of the antipsychotic treatment on the long-term potentiation of the neural pathways associated with psychotic disorders and DRMDs is still minimal. This study investigated the prevalence, incidence, persistence, and clinical correlates of DRMDs in patients during their first years after disease onset.

METHODS

The Genetic Risk and Outcome of Psychosis study is a longitudinal study of 1120 relatively young patients with nonaffective psychosis and a mean age and illness duration of 27 and 4 years, respectively. The following drug-related movement disorders were assessed at baseline and at the 3-year follow-up: parkinsonism, akathisia, tardive dyskinesia, and tardive dystonia. We determined prevalence, incidence, and persistence and investigated clinical correlates at and over the baseline and follow-up assessment.

RESULTS

Patients' mean age and illness duration at baseline were 27.1 and 4.3 years, respectively. In 4 patients, 1 developed a DRMD over the 3-year study period. Prevalence, incidence, and persistence rates were highest for parkinsonism (32%, 21%, and 53%) followed by akathisia (9%, 5%, and 17%) and tardive dyskinesia (4%, 3%, and 20%). Significant associations were found between DRMDs and the patients' age, IQ, and psychopathology.

CONCLUSIONS

The prevalence, persistence, and incidence of DRMDs in this sample were high despite the relatively young age, recent onset of the disorder, and treatment primarily with second-generation antipsychotics. These findings emphasize that screening, diagnosis, and treatment of DRMDs are still important.

Authors+Show Affiliations

From the *Innova, GGZ Centraal, Amersfoort; and †Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, the Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

28141621

Citation

Mentzel, Thierry Q., et al. "High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders." Journal of Clinical Psychopharmacology, vol. 37, no. 2, 2017, pp. 231-238.
Mentzel TQ, Lieverse R, Bloemen O, et al. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. J Clin Psychopharmacol. 2017;37(2):231-238.
Mentzel, T. Q., Lieverse, R., Bloemen, O., Viechtbauer, W., & van Harten, P. N. (2017). High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. Journal of Clinical Psychopharmacology, 37(2), 231-238. https://doi.org/10.1097/JCP.0000000000000666
Mentzel TQ, et al. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. J Clin Psychopharmacol. 2017;37(2):231-238. PubMed PMID: 28141621.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. AU - Mentzel,Thierry Q, AU - Lieverse,Ritsaert, AU - Bloemen,Oswald, AU - Viechtbauer,Wolfgang, AU - van Harten,Peter N, AU - ,, PY - 2017/2/1/pubmed PY - 2017/6/27/medline PY - 2017/2/1/entrez SP - 231 EP - 238 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 37 IS - 2 N2 - BACKGROUND: Drug-related movement disorders (DRMDs) reduce quality of life and contribute to medication noncompliance of patients with psychotic disorders. Little is known about the epidemiology of DRMDs in relatively young patients a few years after onset of psychosis. This is an important period to study, as the impact of the antipsychotic treatment on the long-term potentiation of the neural pathways associated with psychotic disorders and DRMDs is still minimal. This study investigated the prevalence, incidence, persistence, and clinical correlates of DRMDs in patients during their first years after disease onset. METHODS: The Genetic Risk and Outcome of Psychosis study is a longitudinal study of 1120 relatively young patients with nonaffective psychosis and a mean age and illness duration of 27 and 4 years, respectively. The following drug-related movement disorders were assessed at baseline and at the 3-year follow-up: parkinsonism, akathisia, tardive dyskinesia, and tardive dystonia. We determined prevalence, incidence, and persistence and investigated clinical correlates at and over the baseline and follow-up assessment. RESULTS: Patients' mean age and illness duration at baseline were 27.1 and 4.3 years, respectively. In 4 patients, 1 developed a DRMD over the 3-year study period. Prevalence, incidence, and persistence rates were highest for parkinsonism (32%, 21%, and 53%) followed by akathisia (9%, 5%, and 17%) and tardive dyskinesia (4%, 3%, and 20%). Significant associations were found between DRMDs and the patients' age, IQ, and psychopathology. CONCLUSIONS: The prevalence, persistence, and incidence of DRMDs in this sample were high despite the relatively young age, recent onset of the disorder, and treatment primarily with second-generation antipsychotics. These findings emphasize that screening, diagnosis, and treatment of DRMDs are still important. SN - 1533-712X UR - https://www.unboundmedicine.com/medline/citation/28141621/High_Incidence_and_Prevalence_of_Drug_Related_Movement_Disorders_in_Young_Patients_With_Psychotic_Disorders_ L2 - http://dx.doi.org/10.1097/JCP.0000000000000666 DB - PRIME DP - Unbound Medicine ER -